GlaxoSmithKline (GSK) Reports Q4 EPS of 24.8p

(Updated)

GlaxoSmithKline (NYSE: GSK) reported Q4 EPS of 24.80p, better than the analyst estimate of 24.50p. Revenue for the quarter came in at GBP8.9 billion versus the consensus estimate of GBP9.02 billion.

2020 guidance

• Expect Adjusted EPS to decline -1% to -4% CER
• Expect 80p dividend for 2020

For earnings history and earnings-related data on GlaxoSmithKline (GSK) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Goldman Sachs reports global fund inflows for week of July 8
• Occidental Petroleum releases Q2 2026 earnings considerations